Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1996-6-13
pubmed:abstractText
Murine hepatitis virus strain 3 (MHV-3) produces a strain-dependent spectrum of disease. The development of liver necrosis has been shown to be related to production of a unique macrophage procoagulant activity (PCA), encoded by the gene fgl-2, in susceptible mice. These studies were designed to examine the influence of Th1/Th2 cells on resistance/susceptibility and production of macrophage PCA in resistant (A/J) and susceptible (BALB/cJ) strains of mice following infection with MHV-3. Immunization of A/J mice with MHV-3 induced a Th1 cellular immune response, and one Th1 cell line (3E9.1) protected susceptible mice and inhibited PCA production by macrophages both in vitro and in vivo. In contrast, immunization of BALB/cJ mice with an attenuated variant of MHV-3 derived from passaging MHV-3 in YAC-1 cells resulted in a Th2 response. Transfer of spleen cells and T cell lines from immunized BALB/cJ mice failed to protect naive susceptible syngeneic mice from infection with MHV-3 and augmented macrophage PCA production to MHV-3 in vitro. However, serum from immunized BALB/cJ mice contained high titrated neutralizing Ab that protected naive BALB/cJ animals from lethal primary MHV-3 infection. These results demonstrate that susceptible BALB/cJ mice generate a Th2 response following MHV-3 infection and that these Th2 cells neither inhibit MHV-3-induced macrophage PCA production nor protect naive mice from MHV-3 infection. The results suggest that Ab protects against primary infection but cannot eradicate ongoing infection. Thus, these data define the differential role of Th1/Th2 lymphocytes in primary and secondary MHV-3 infection and emphasize the importance of PCA in the pathogenesis of MHV-3 infection.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
156
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3342-9
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:8617959-Animals, pubmed-meshheading:8617959-Antibodies, Viral, pubmed-meshheading:8617959-Blood Coagulation Factors, pubmed-meshheading:8617959-Cell Line, pubmed-meshheading:8617959-Coronavirus Infections, pubmed-meshheading:8617959-Disease Susceptibility, pubmed-meshheading:8617959-Female, pubmed-meshheading:8617959-Hepatitis, Viral, Animal, pubmed-meshheading:8617959-Immunity, Innate, pubmed-meshheading:8617959-Immunization, Passive, pubmed-meshheading:8617959-Immunotherapy, Adoptive, pubmed-meshheading:8617959-Macrophages, pubmed-meshheading:8617959-Mice, pubmed-meshheading:8617959-Mice, Inbred A, pubmed-meshheading:8617959-Mice, Inbred BALB C, pubmed-meshheading:8617959-Mice, Inbred C57BL, pubmed-meshheading:8617959-Murine hepatitis virus, pubmed-meshheading:8617959-Spleen, pubmed-meshheading:8617959-Th1 Cells, pubmed-meshheading:8617959-Th2 Cells, pubmed-meshheading:8617959-Viral Vaccines
pubmed:year
1996
pubmed:articleTitle
Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
pubmed:affiliation
Department of Surgery, The Toronto Hospital-University of Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't